Sponsored by:
7:00-7:45am
Registration/Coffee
7:45-8:45
Product Theatre Breakfast - (Non-CME) Addressing Risk of HF Rehospitalization With an Additional Guideline-Recommended Medication Payal Kohli, MD Learning Objectives: - Discuss the increased risk of rehospitalization for HF with additional HFH - Review an outcome study in high-risk patients with HFrEF Supported by: Merck
8:45-9:00
Introductions, Welcome and Program Overview Drs. Lori Daniels and Alan Maisel
Session I: Acute Coronary Syndrome and Troponin Allan Jaffe, MD (Moderator)
9:00-9:15
hsTroponin in the Emergency Department: 0/1h Strategy Frank Peacock, MD
9:15-9:35
STATE OF THE ART TALK How Low Can You Go? The Evolution of hsTroponin and Future Applications Fred Apple, PhD
9:35-9:50
Point of Care hsTroponin for Early Rule-Out of MI: Dawn of a New Age Pedro Lopez-Ayala, MD, MSc
9:50-10:05
Biomarkers and Type 1 vs Type 2 MI Yader Sandoval, MD
10:05-10:30
Acute Coronary Syndrome Panel Q&A Allan Jaffe, MD (Moderator)
10:30-10:50
Coffee Break/Visit Exhibits
Session II: Biomarkers in Heart Failure and CVD Prevention Alan Maisel, MD (Moderator)
10:50-11:05
Getting to GDMT Targets with STRONG-HF Biomarkers Gregg Fonarow, MD
11:05-11:20
Cardiologists as Diabeticians: Biomarkers and SGLT2i/GLP1a Treatments David Berg
11:20-11:35
Uncovering the Real Pandemic – Leveraging Biomarkers to Crack CVD Prevention Christopher deFilippi, MD
11:35-11:50
Breast Arterial Calcification for Cardiovascular Risk Prediction in Women Lori Daniels, MD
11:50-12:05pm
Sizing up the Inferior Vena Cava: A Biomarker for all of Heart Failure Ori Ben-Yehuda, MD
12:05-12:30
Heart Failure Case Q&A Panel Nick Wettersten, MD (Presenter)
12:30-1:30
Product Theatre Luncheon - (Non-CME) Is OZEMPIC® Right for Your Patients With Established ASCVD and T2D? Matthew Budoff, MD Supported by: Novo Nordisk
Session III: Cardiometabolic Biomarkers and Novel Approaches Lori Daniels, MD (Moderator)
1:30-1:50
Integrating Biomarkers into Outcomes Trials Ori Ben-Yehuda, MD
1:50-2:05
Two Heads are Better than One: Joining Biomarkers with CAC for Prediction of ASCVD Matthew Budoff, MD
2:05-2:20
Practical Application of Biomarkers for Cardiac Rehab and Prevention: Where Biomarkers of Lipids, Glycemia and Inflammation Intersect Pam Taub, MD
2:20-2:35
Who Invited the Kidney to the Heart Party? Implications of Cardiorenal Biomarkers Nick Wettersten, MD
2:35-2:50
Biomarkers Come to Hollywood Alan Wu, PhD
2:50-3:05
Biomarkers in Cardio-Oncology – More than NTpro, Tn and a Buzzword Anya Narezkina, MD
3:05-3:25
Session IV: Biomarkers - The Next Generation: EP, Cath Lab and AI Alan Maisel, MD (Moderator)
3:25-3:40
Next-Generation Machine Learning with 12-lead ECGs to Target and Treat Arrhythmias David Krummen, MD
3:40-3:55
Biomarkers and Optimizing Therapies for Patients Arrhythmia and Device Patients Riki Green, MD
3:55-4:10
The Holy Grail: Biomarkers of Vulnerable Plaque David Erlinge, MD
4:10-4:25
Leveraging Imaging Biomarkers and AI for Radiologic Diagnoses Albert Hsiao, MD
4:25-4:40
Putting it All Together: Artificial Intelligence in ACS and Heart Failure Alan Maisel, MD
4:40-4:55
Q&A
4:55-5:00
Concluding Remarks Drs. Lori Daniels and Alan Maisel
5:00-6:00
Wine and Cheese Reception and Poster Session